Progenics Pharmaceuticals, Inc. (PGNX) Misses Q4 EPS by 3c; Founder Maddon to Retire
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Join SI Premium – FREE
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) reported Q4 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $7.37 million.
The company also announced that company founder Paul J. Maddon, M.D., Ph.D. has retired as chief science officer of the company. He continues as a member and vice chair of the Progenics board of directors.
For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.
The company also announced that company founder Paul J. Maddon, M.D., Ph.D. has retired as chief science officer of the company. He continues as a member and vice chair of the Progenics board of directors.
For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
- Bernstein on Tesla: 'Widespread deployment of FSD is 5 - 10 years away'
- Innodata (INOD) Awarded New Programs from "Magnificent Seven" Big Tech Customer Valued at Approximately $20 Million in Annualized Run Rate Revenue
Create E-mail Alert Related Categories
Earnings, Management ChangesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
